At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01779 LONGBIO-B
Trading 11-03 10:57:27
50.000
-1.400
-2.72%
High59.050
Low48.380
Vol63.30K
Open59.050
D1 Closing51.400
Amplitude20.76%
Mkt Cap3.82B
Tradable Cap3.75B
Total Shares76.32M
T/O3.19M
T/O Rate0.08%
Tradable Shares75.06M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
LongBio Pharma Updates Articles of Association, Clarifies Capital Structure, Governance and Dividend Policy
LongBio Pharma (Suzhou) Co Ltd is a China-based company primarily engaged in the in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases. The Company's research and development platforms mainly include High-Affinity Antibody Discovery Platform and Bi-functional Antibody Development Platform. The Company's drug treatment direction mainly includes seasonal allergic rhinitis (AR), chronic spontaneous urticaria (CSU), allergic asthma, food allergy and other allergic diseases, also paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated kidney diseases, which includes IgA nephropathy (IgAN), C3 glomerulopathy (C3G) and lupus nephritis (LN) and other complement related indications. The Company mainly operates its businesses in the domestic market.